Biogen (BIIB) Projected to Post Earnings on Thursday

Biogen (NASDAQ:BIIB) is projected to post its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect Biogen to post earnings of $3.89 per share and revenue of $2.3356 billion for the quarter. Biogen has set its FY 2025 guidance at 15.500-16.000 EPS.Individuals can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, October 30, 2025 at 8:30 AM ET.

Biogen (NASDAQ:BIIB) last released its earnings results on Thursday, July 31st. The biotechnology company reported $5.47 EPS for the quarter, beating the consensus estimate of $3.93 by $1.54. The company had revenue of $2.65 billion during the quarter, compared to analysts’ expectations of $2.32 billion. Biogen had a return on equity of 13.85% and a net margin of 15.31%.The business’s revenue was up 7.3% on a year-over-year basis. During the same period in the prior year, the business posted $5.28 EPS. On average, analysts expect Biogen to post $16 EPS for the current fiscal year and $17 EPS for the next fiscal year.

Biogen Stock Performance

BIIB stock opened at $150.43 on Tuesday. The company has a current ratio of 2.50, a quick ratio of 1.79 and a debt-to-equity ratio of 0.36. The firm has a market cap of $22.06 billion, a P/E ratio of 14.38, a P/E/G ratio of 1.19 and a beta of 0.13. Biogen has a 12-month low of $110.04 and a 12-month high of $187.28. The stock’s 50 day simple moving average is $143.32 and its 200 day simple moving average is $132.69.

Insider Activity

In other news, insider Priya Singhal sold 517 shares of the stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $133.55, for a total value of $69,045.35. Following the completion of the transaction, the insider owned 5,772 shares of the company’s stock, valued at approximately $770,850.60. This represents a 8.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 0.18% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. WFA of San Diego LLC bought a new position in shares of Biogen in the second quarter worth $32,000. MUFG Securities EMEA plc bought a new position in shares of Biogen in the second quarter worth $54,000. Sivia Capital Partners LLC bought a new position in shares of Biogen in the second quarter worth $216,000. B. Riley Wealth Advisors Inc. bought a new position in shares of Biogen in the second quarter worth $250,000. Finally, NewEdge Advisors LLC grew its stake in shares of Biogen by 13.4% in the second quarter. NewEdge Advisors LLC now owns 2,673 shares of the biotechnology company’s stock worth $336,000 after purchasing an additional 316 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Jefferies Financial Group assumed coverage on Biogen in a research report on Thursday, September 25th. They set a “buy” rating and a $190.00 price target on the stock. Truist Financial assumed coverage on Biogen in a research report on Monday, July 21st. They set a “hold” rating and a $142.00 price target on the stock. Wedbush upped their price target on Biogen from $129.00 to $135.00 and gave the company a “neutral” rating in a research report on Tuesday, October 14th. William Blair reissued an “outperform” rating on shares of Biogen in a research report on Wednesday, September 24th. Finally, Weiss Ratings raised Biogen from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday. Eleven investment analysts have rated the stock with a Buy rating and twenty have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $180.69.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.